Frontlight ResearchEarly access
Lung cancer trials in South Korea
170 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1Taking peopleOpen-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 392 worldwide
- Run by
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00 - Phase 1/2Taking peopleA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Where
- Seoul
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00 - Phase 3Taking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Cheongju-si, Goyang-si, Incheon, Seoul
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - No phaseNot yet taking people in South KoreaRepotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion
- Where
- Seoul
- Age
- 12 years and over
- People
- 10
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07599007 - Phase 1Taking peopleA Study of PHN-012 in Patients With Advanced Solid Tumors
- Where
- Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 165 worldwide
- Run by
- Pheon Therapeutics
See details and how to joinNCT07127874 - Phase 3Taking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Where
- Jinju, Seoul
- Age
- 18 years and over
- People
- 830 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00 - Phase 1Taking peopleA Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
- Where
- Cheongju Chungbuk, Seongnam-si, Gyeonggi-do, Seoul
- Age
- 18 years to 90 years
- People
- 380 worldwide
- Run by
- Amgen
See details and how to joinNCT07037758 - Phase 1/2Taking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- Gyeonggi-do, Seoul
- Age
- 12 years and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - Phase 1Taking peopleA Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
- Where
- Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 40 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391670 · EU 2025-521639-34-00 - Phase 1Taking peoplePhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Seoul
- Age
- 18 years to 100 years
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - Phase 1/2Taking peopleA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 102
- Run by
- GI Innovation, Inc.
See details and how to joinNCT07172802 - Phase 1/2Taking peopleA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Where
- BundangGu SeongnamSi, Cheongju-si, GangnamGu, SeodaemunGu, Seongnam-si, Seoul, SongpaGu
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00 - Phase 2Taking peopleLazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
- Where
- Seoul
- Age
- 19 years and over
- People
- 47
- Run by
- Sehhoon Park
See details and how to joinNCT06106802 - Phase 2Taking peopleClinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
- Where
- Seoul
- Age
- 19 years and over
- People
- 50
- Run by
- Sehhoon Park
See details and how to joinNCT06830694 - Phase 1Taking peopleA Phase 1/1b Study of IAM1363 in HER2 Cancers
- Where
- Seoul
- Age
- 18 years and over
- People
- 383 worldwide
- Run by
- Iambic Therapeutics, Inc
See details and how to joinNCT06253871 - Phase 2Not yet taking people in South KoreaLurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer
- Where
- Seoul
- Age
- 20 years and over
- People
- 69
- Run by
- Yonsei University
See details and how to joinNCT07640932 - Phase 1/2Active, not recruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Where
- Gyeonggi-do, Seoul
- Age
- 18 years and over
- People
- 796 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05150691 - Phase 1/2Taking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Seoul
- Age
- 18 years to 100 years
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - No phaseNot yet taking people in South KoreaEffect of Mechanical Power-based Lung-protective Ventilation During One-lung Ventilation
- Where
- Seoul
- Age
- 19 years and over
- People
- 164
- Run by
- Samsung Medical Center
See details and how to joinNCT07772804 - Phase 3Active, not recruitingPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Where
- Goyang-si, Namdong-gu, Seoul, Suwon
- Age
- 18 years and over
- People
- 582 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00 - Phase 1/2Taking peopleStudy of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- Where
- Seongnam, Seoul
- Age
- 18 years and over
- People
- 244 worldwide
- Run by
- Taiho Pharmaceutical Co., Ltd.
See details and how to joinNCT04683250 - Phase 2Taking peopleA Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy
- Where
- Seoul
- Age
- 19 years and over
- People
- 1,173
- Run by
- Samsung Medical Center
See details and how to joinNCT07774520 - Phase 1/2Taking peopleA Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- Where
- Cheongju-si, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 201 worldwide
- Run by
- Yuhan Corporation
See details and how to joinNCT06616766 - No phaseTaking peopleThe Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]
- Where
- Incheon, Jungbuk, Seongnam, Seoul, Ulsan
- Age
- 20 years and over
- People
- 797
- Run by
- Samsung Medical Center
See details and how to joinNCT02688894